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ABSTRACT 
Beyond the motor disability, Parkinson’s disease (PD) is also characterized by an early appearance of 
psychiatric symptoms such as apathy, depression, anxiety and cognitive deficits, which can entail 
dementia and psychosis in later stages. While current treatments may provide some level of symptomatic 
relief, their use is limited by the development of adverse effects such as impulse-control disorders. There 
is thus a medical need for targets with novel modes of action to treat these aspects of PD. In this context, 
we investigated GPR88, an orphan G-protein coupled receptor that is associated with psychiatric disorders 
and highly enriched in the striatum, where it exerts an inhibitory control over neurotransmitter systems 
that are compromised in PD. To evaluate the potential of GPR88 as a target for the treatment of the 
psychiatric symptoms of PD, we knocked-down (KD) its expression in sensorimotor (dorsolateral, DLS) 
or associative (dorsomedial, DMS) striatal areas in a translational rat model of early PD. Our findings 
indicate that Gpr88-KD in the DMS, but not DLS, reduced the alterations in mood, motivation and 
cognition that characterized the model, through modulation of the expression of regulator of G-protein 
signaling 4 (Rgs4) and of transcription factor ∆FosB. Furthermore, the rat model of PD exhibited allostatic 
changes in striatal activity markers that may be related to patterns observed in patients, and which were 
reduced by Gpr88-KD. Taken together, these results thus highlight the relevance of GPR88 as a 
therapeutic target for the psychiatric symptoms of PD. 
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INTRODUCTION 
While Parkinson’s disease (PD) is classically defined as a motor disorder, it also entails psychiatric 
symptoms that are a major burden on patients’ quality of life (1). Many of these symptoms have been 
grouped as part of a “hypodopaminergic” syndrome resulting from the loss of nigrostriatal neurons, which 
includes apathy, depression, anxiety and cognitive impairment, and affects 35 to 85% of patients 
depending on the symptom (2, 3). Apathy in particular, defined as a decrease in motivational drive, has 
emerged as a core symptom of PD, and is present in up to 70% of patients (4). It is often associated with 
cognitive impairment, as apathetic patients are found to have worse executive dysfunction and an 
increased risk of developing dementia in later stages (5). Psychosis also develops in up to 60% of patients, 
and is an additional risk factor for dementia(6).  
A remarkable feature of these symptoms is that they frequently emerge years before the onset of motor 
impairments (7, 8). At the time of diagnosis, studies have for instance found that 37% of patients already 
suffered from depression, 27% from apathy, 17% from anxiety (9), 20-40% from cognitive dysfunction 
(10), and 42% reported minor psychotic phenomena, such as passage and presence hallucinations (11).  
While dopaminergic medications can efficiently treat some of these aspects (3, 4), their effect is hindered 
by the frequent development of “hyperdopaminergic” symptoms such as impulse-control disorders, which 
can have disastrous consequences (2). Furthermore, existing treatments for cognitive impairment and 
psychosis have variable efficacy and limiting side effects (6, 12). There is thus a crucial unmet medical 
need for the development of new symptomatic treatments to manage these symptoms.   
In this context, the orphan G-protein Coupled Receptor 88 (GPR88) is emerging as a particularly suited 
target. GPR88 has been associated with Bipolar Disorder and Schizophrenia (13, 14), and deleterious 
mutations were found to induce profound learning deficits and a hyperkinetic movement disorder in 
humans (15). GPR88 is mainly expressed in striatal Medium Spiny Neurons (MSN) at the level of the 
corticostriatal synapse (16), where it exerts an inhibitory control over monoamine and neuropeptide 
neurotransmission through Gi/o coupling (17). Indeed, Gpr88-KO mice are hypersensitive to D2 agonists, 
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and their MSNs exhibit increased signaling of delta opioid and muscarinic receptors (18, 19). Given these 
characteristics, it is not surprising that Gpr88-KO mice were found to have impaired affective, goal-
directed, cognitive and sensorimotor behaviors (18–22).  
GPR88’s restricted localization and wide-ranging effects have thus made it an interesting therapeutic 
target for disorders of the basal ganglia. For instance, preclinical studies have already revealed promising 
results in a model of schizophrenia (23) and potential involvement in alcohol use disorder (24). Given that 
GPR88 exerts inhibitory control over the key neurotransmitter systems that are altered in PD, we 
hypothesized that inhibiting GPR88 in the striatum could have a therapeutic effect by potentiating 
endogenous neurotransmission.  
In order to evaluate GPR88’s potential as a therapeutic target for the psychiatric symptoms of PD, we first 
developed a translational model of early PD in rats by reproducing the loss of dopamine (DA) that is 
observed in the first stages of the disease, specifically affecting sensorimotor territories of the striatum 
(25), through stereotaxic injections of the 6-hydroxydopamine (6OHDA) toxin. As no antagonists are 
currently available for this receptor, we then used a localized gene therapy approach to knock-down the 
expression of Gpr88 (Gpr88-KD). This strategy enabled us to assess the effects of Gpr88-KD in the 
sensorimotor and associative areas of the striatum independently (dorsolateral and dorsomedial striatum in 
rodents, respectively), the latter having been frequently associated with psychiatric symptoms in patients 
(26). The effects of both procedures were then evaluated at behavioral and molecular levels.   
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MATERIALS AND METHODS 
Animals 
Animal studies were authorized by an ethical committee reporting to the French Ministry of Agriculture 
(APAFIS reference #3669-2016011817516297) and were conducted in the in-house SPF animal facility, 
which was approved by the Veterinary Inspection Office (agreement reference B75-13-19). The animals 
were handled throughout the study in compliance with the European Union 2010 Animal Welfare Act, and 
the 2010/63 French directive. The procedures were reported following the ARRIVE guidelines (27). 
The experiments were performed with male Sprague-Dawley rats that weighed 300g on average at the 
time of the first surgery (7 weeks old). The rats were first housed in groups of four until the first surgery, 
after which they were housed in pairs. Animal well-being was checked daily by the experimenters or the 
animal facility staff. The cages were ventilated and enriched with cardboard tunnels, and food and water 
were available ad libitum. The facility used a 12h day/night cycle starting at 8 AM, and controlled the 
temperature and the humidity levels daily. 
Study design  
A schematic representation of the study design and timeline is presented in the supplementary figures 
(Fig. S1). Two hypotheses were emitted at the beginning of the project, namely that (i) the partial lesion of 
the rat DLS would reproduce some of the psychiatric symptoms of PD, and that (ii) inactivating Gpr88 in 
different striatal areas of the lesioned rats would affect different behavioral parameters. In order to test 
each hypothesis, several experimental groups were designed. (i) To assess the effect of the loss of DA, 
two groups of animals were compared: 6OHDA-injected vs SHAM-injected. The rats from both groups 
were also transduced with an inactive control LV miR-neg sequence in the different striatal compartments. 
(ii) To determine the effects of Gpr88 inactivation in 6OHDA-lesioned rats, stereotaxic injections of 
lentiviruses were performed either in the dorsolateral (DLS), dorsomedial (DMS) or ventral striatum (VS; 
Nucleus Accumbens Core). However, as experiments were underway, no major effects of Gpr88 
inactivation in the ventral striatum were observed, while intriguing interactions were emerging between 
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the dorsolateral and dorsomedial tiers of the striatum. For the sake of clarity, we thus decided to limit the 
scope of this article to the DLS-DMS interactions in both the effects of the lesion and of Gpr88-KD. 
The data were accumulated over 17 replication batches. Each batch consisted of 6-10 animals that were 
randomly distributed across the different experimental conditions, making sure that no 2 rats of the same 
conditions were housed together. In order to comply with the 3Rs guidelines, the appropriate sample size 
was calculated based on behavioral data from preliminary experiments, using the G*Power3 software 
(28). To reach a statistical power of 0.9 with the alpha level set at 0.05, the recommended sample size was 
of 9-10 animals per condition, depending on the behavioral task. Replication batches were thus stopped 
once the recommendation was met. 
Finally, we observed an important level of cumulative variability in the quality and extent of the lesions 
and lentiviral transductions. In order to limit the effect of this variability and enhance the reproducibility 
of our findings, strict inclusion criteria were applied. First of all, the DA loss had to affect at least 20% of 
the DLS, but no more than 15% of the neighboring DMS and VS. Next, sufficient GFP fluorescence had 
to be present in the area targeted with LV miR-Gpr88. Furthermore, in the rare occurrences of adverse 
events (such as important weight loss or inflammatory reactions), the rats were excluded from the 
statistical analyses.  
Stereotaxic injections of 6OHDA and lentiviral vectors 
Before the beginning of the surgeries, the animals were first anaesthetized with 4% isoflurane (IsoVet, 
Osalia) in an induction chamber (Minerve Veterinary Equipment, Esternay, France) for 5 minutes before 
being placed into a Kopf stereotaxic surgery apparatus (Phymep, Paris, France). Anesthesia was 
maintained throughout the surgery with an isoflurane pump (Univentor, Zejtun, Malta). General and 
localized analgesia was induced with subcutaneous injections of Buprecare (buprenorphine; 0,05mg/kg) 
(Axience) and Xylovet (lidocaine; 17,5mg/kg) (Ceva) before beginning the surgery. 4µl of a solution of 
6OHDA (3µg/µl, 12µg total per hemisphere) in saline + 0.02% ascorbic acid (all chemicals from Sigma) 
or of a control solution (saline + 0.02% ascorbic acid only) were then injected bilaterally in the DLS using 
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a 10µL Hamilton syringe (Phymep, Paris, France). The coordinates were as follow: anteroposterior (AP) + 
0,7mm; mediolateral (ML) ± 3,8mm; dorsoventral (DV) -5,5mm (2µl) and -4,5mm (remaining 2µl) from 
bregma(29). The injections were performed at a rate of 0.5µl/min, and the syringe was left in place for 3 
minutes after the end of each injection to allow for proper diffusion of the toxin. Following the surgeries, 
the wellbeing of the animals was checked daily. While some rats transiently lost weight, they typically 
recovered within 3 to 5 days.  
Lentivirus production and stereotaxic injection 
The lentiviral vectors were generated at the in-house iVector platform, using the BLOCK-iT Pol II miR 
RNAi expression vector kit (Invitrogen). The vector construct contained an engineered miR sequence to 
drive Gpr88 knock-down. The modified miR consisted of a shRNA inserted within the miRNA 155 
flanking sequences. One of the shRNA complementary sequences was designed to target either Gpr88 
mRNA (“miR-Gpr88”), or a control sequence that is not expressed in the genome (“miR-neg”). The use of 
a shRNA sequence allowed for high specificity of RNA interference under control of the PGK promoter, 
which is best suited for in vivo studies. The lentiviruses were stored in PBS at -80°C, at an average of 
1,6x105 transducing units (TU) /µL.  
6µL of the lentivirus solution were bilaterally injected in the DLS or DMS two weeks after the 6OHDA 
injections, following the same general surgical procedure. The coordinates were however different, as the 
lentiviruses were injected at 4 different sub-sites per hemisphere (8 total) to insure sufficient knock-down 
of Gpr88 expression. When targeting the DLS, the coordinates were the following: (1) AP +1,2 mm; ML 
±3,6 mm; DV -5,5mm and -4,5mm (2) AP +0,2 mm, ML ±4mm, DV -5,5mm and -4,5mm from bregma. 
Regarding the DMS, the coordinates were: (1) AP +1,2 mm; ML ±2 mm; DV -5,5mm and -4,5mm (2) AP 
+0,2 mm, ML ±2,2mm, DV -5,5mm and -4,5mm from bregma.  
Behavioral tests 
Each test was set up by the same experimenter and around the same time of day for each batch of animals, 
in between 9 AM and 4 PM.  The experimenter was unaware of the status of the rats, which were brought 
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in the testing rooms one hour before the beginning of the task, in order for them to acclimate to the 
environment. The luminosity was controlled for every experiment (35 lux), and the testing apparatus were 
cleaned before each test and between rats with a disinfectant solution (Aniospray, Dutscher). 
Actimeter - General motor and exploratory behavior was assessed for 15 minutes using the Panlab Infrared 
Actimeter (Harvard Apparatus, Holliston, MA, USA). Horizontal, stereotyped and vertical movements 
were automatically quantified and cumulated into 5-minute segments.  
Sucrose preference - Rats were isolated in enriched individual cages for 72h, during which time they were 
given access to two bottles containing either tap water, or tap water supplemented with 0,5% sucrose 
(Sigma). The first 24h were considered as an acclimation phase, and were not included in the analysis. 
After 48h, the position of the bottles was inverted to avoid side preference effects. Bottles were weighed 
daily in order to calculate the amount of consumed liquids. Sucrose preference was calculated as the 
percentage of sucrose intake / total intake. However, as the level of sucrose preference exhibited by 
control rats was lower than what we had observed during pilot experiments (at 0,25% sucrose), the 
concentration had to be re-evaluated after several batches of animals (0,5%). For this reason, the number 
of data points for this experiment is relatively lower. General consummatory behavior was also tracked by 
weighing the food dispenser at the beginning and end of the isolation phase.  
Social Novelty Discrimination (SND) - Social interaction and selective attention were then evaluated using 
the social novelty discrimination task (SND) as previously described (23, 30). As this behavioral paradigm 
requires a preliminary isolation phase, we performed it at the end of the sucrose preference test. Briefly, a 
first juvenile was placed into the home cage of the tested rat for a presentation period (P1) of 30 min. The 
time spent by the tested rat investigating the juvenile (anogenital sniffing, pursuing, allogrooming) was 
timed manually for the first 5 min. At the end of P1, a second juvenile was introduced in the cage, and the 
time spent investigating the novel vs the familiar juvenile was timed by the experimenter (presentation 
period P2). The “discrimination ratio” was calculated as the time spent by the tested rat interacting with 
the novel juvenile over the familiar juvenile during P2. 
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Prepulse Inhibition (PPI) - Sensorimotor gating was assessed using an auditory prepulse inibition 
apparatus (IMETRONIC, Pessac, France). The adapted protocol (31) contained three phases: a first 
acclimation period of 10 minutes, followed by a phase of habituation to the startle stimulus, and ending 
with the testing phase. During the acclimation phase, a background white noise of 60dB was played, 
which persisted throughout the whole testing session. The habituation phase consisted of 10 startle-
inducing auditory “pulses” played at 110dB (7Khz, 100ms), and at random intervals between 15-30 
seconds. During the testing phase, four different types of stimuli were presented: a pulse alone (110dB), a 
prepulse-pulse pairing, a prepulse alone, or no sound (to assess background movement). The prepulses 
(20ms, 70-80dB) preceded the startle pulses by 100ms. Each condition was presented 10 times in a 
pseudo-randomized order, at random intervals between 15 and 30 seconds. Prepulse inhibition (%PPI) was 
measured as the reduction in startle response during prepulse–pulse conditions compared to pulse-alone 
trials.  
Forced Swim Test (FST) - The rats were placed in a transparent cylinder filled up to 35 cm with 24°C (±1) 
water for 5 minutes, and recorded using a digital camera. A trained experimenter blinded to the conditions 
then analyzed the behavior of the animals using a previously described sampling method (32), calculating 
immobility, swimming, climbing and diving counts.  
Immunolabelling and in situ hybridization  
Following the end of the behavioral procedures (after 2-4 days), the rats were anaesthetized in an 
isoflurane chamber and decapitated. The brains were rapidly removed and snap-frozen for 90 seconds in 
isopentane at -55°C (Carlo Erba Reagents). Coronal cryosections (12µm) of the striatum were used to 
control for the presence and extent of GFP signal in the targeted areas. The slices were then post-fixed in 
4% PFA for 30 minutes at 4°C in order to perform immunolabelling and in situ hybridization experiments.  
Immunolabelling procedures were adapted from a previously published protocol (33) using primary 
antibodies directed against Tyrosine Hydroxylase (TH) (Millipore MAB318, 1:400) and ∆FosB (Abcam 
AB11959, 1:500). TH immunolabelling was completed using a fluorophore-coupled secondary antibody 
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(Alexa Fluor 647, Invitrogen A21235, 1:1000), while ∆FosB required DAB revelation for best results 
(BA-2000 secondary antibody, 1:250, and PK6100 kit from Vector Laboratories) (Fig. S2A,C).   
In situ hybridization (ISH) was performed with antisense digoxygenin-labeled complementary RNA 
probes designed to recognize Gpr88, 67-kDa glutamate decarboxylase (Gad67), proenkephaline (Penk), 
prodynorphine (Pdyn) mRNAs as previously described (23) (Fig. S2B, D). A new probe was also 
designed following the same procedures to target regulator of G-protein signaling 4 (Rgs4) mRNA 
(GenBank accession number: NM017214, targeted nucleotides: 325 to 604). 
Digitization and semi-quantitative analysis - Slides were then digitized using the Axio Scan.Z1 and ZEN 
software (Zeiss, Oberkochen, Germany). The resulting images were exported for processing in Fiji (NIH, 
Bethesda, MD, USA) (34). As fluorescent and colorimetric stainings are not stoichiometrically related to 
biological content, the signal intensity was not quantified. Instead, a threshold was determined using 
control slides (secondary antibody alone/sense probe) or control areas within a slice (corpus callosum), 
and applied to all of the images from a same experiment. To evaluate the loss of dopaminergic terminals, 
the TH-positive signal was then quantified in each striatal area (DLS, DMS, ventral striatum) of every 
lesioned rat according to previously published methods(35). Regarding the nuclear markers (∆FosB and 
all of the ISH targets), a fixed-size region of interest was drawn in the DLS and DMS, and the total signal-
positive area was quantified (see Fig.S2E). For each striatum, the signal was measured over at least 3 
anteroposterior locations between AP +0,2 mm and +1,2 mm, and averaged. The values were then 
normalized to those obtained in control rats (SHAM + miR-neg). A Fiji macro script was written to 
automatize the process. As the lesion and transduction extent varied, each striatum (2/brain) was 
considered as a biological replicate for statistical analyses.  
Statistical Analyses 
Data from the experiments were analyzed using the Prism 6.0 software (GraphPad Software Inc, La Jolla, 
CA, USA). Different tests were performed depending on the nature of the data and the driving hypotheses 
that were exposed in the “study design” section. For instance, regarding behavioral data, to assess the 
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effects of the lesion (hypothesis 1), the two groups (SHAM-neg vs 6OHDA-neg) were compared using 
two-tailed unpaired t-tests, followed by Welch corrections. Then, to evaluate the effects of Gpr88-KD in 
6OHDA-lesioned animals (hypothesis 2), the 6OHDA + miR-Gpr88 groups (DLS and DMS) were 
compared to the 6OHDA + miR-neg animals using one-way ANOVAs followed by Dunnett multiple 
comparison tests, as the data distribution passed normality tests. However, some of the actimeter, PPI and 
SND data required the use of 2-way ANOVAs followed by Sidak or Dunnett corrections where 
appropriate to assess interactions with independent variables (time/prepulse intensity/novelty status). 
Finally, as each striatal area was differentially affected by the 6OHDA lesion, the data from the 
immunolabelling and ISH experiments were analyzed using multiple t-tests followed by Holm-Sidak 
corrections. 
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RESULTS  
6OHDA stereotaxic injections induce a dopaminergic denervation limited to the DLS. 
In order to reproduce the loss of dopaminergic projections to sensorimotor territories of the striatum 
(posterior putamen) observed in early PD, we stereotaxically injected the retrograde toxin 6OHDA in the 
corresponding area in adult male rats (DLS) (36). Control animals (SHAM) were injected with a vehicle 
solution. The toxin induced a partial loss of dopaminergic afferences to the DLS, as indicated by a 48% 
mean reduction of Tyrosine Hydroxylase immunoreactivity over at least 1mm on the anterior-posterior 
axis [p<0.0001, multiple t-tests followed by Holm-Sidak corrections; Fig. 1A, B]. The neighboring 
associative (DMS) and limbic (VS) striatal areas were however not significantly affected by the lesion [in 
the DMS p=0.088; in the VS p=0.671; Fig. 1B]. 
Lentiviral-mediated knock-down efficiently reduces Gpr88 expression. 
Two weeks after the first surgical procedure, lentiviral vectors containing a control miR (miR-neg) or a 
miR directed against Gpr88 (miR-Gpr88) were then stereotaxically injected at multiple sites either in the 
DLS or the DMS of 6OHDA-lesioned rats (Fig. 1C, D). SHAM-lesioned rats were injected with miR-neg 
containing vectors. Expression of Gpr88 mRNA was efficiently reduced in the transduced areas [p<0.0001 
in DLS and DMS, multiple t-tests followed by Holm-Sidak corrections; Fig. 1E, F].  
Partial dopaminergic depletion of the DLS reproduces psychiatric symptoms of PD without 
inducing motor deficits. 
In order to assess whether the limited loss of DA may have an impact on locomotion and thus introduce a 
confounding factor when evaluating other behavioral parameters, motor behavior was assessed at two and 
four weeks after 6OHDA injections by measuring horizontal movements in the Actimeter. This parameter 
was unaffected by the lesion at both timepoints (Fig. 2A, Fig. S3A), as expected with a restricted lesion 
(35). However, although stereotyped behavior in the Actimeter test was also preserved at both timepoints, 
.CC-BY-NC-ND 4.0 International licenseIt is made available under a 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/617456doi: bioRxiv preprint first posted online Apr. 24, 2019; 
13 
 
the number of rearings was reduced at 4 weeks after the lesion [2W-ANOVA: interaction of treatment x 
time, F(2, 44) = 4.66, p=0.015; Fig. 2A], indicating a decrease in novelty exploration behavior (37). 
We then evaluated sensorimotor gating, a parameter that is altered in many basal ganglia disorders 
including PD, and which has been linked to cognitive dysfunction in patients (38). To do so, we used the 
Prepulse Inhibition (PPI) test, which has previously been shown to be sensitive to 6OHDA lesions (39). 
Although the partial lesion of the DLS increased the startle reaction in response to a loud auditory 
stimulus (110dB) [P=0.037, Welch-corrected t-test; Fig. 2B], the level of sensorimotor gating (%PPI) was 
preserved at all levels of prepulse intensity used, suggesting the presence of efficient compensatory 
mechanisms.   
Affective parameters relating to anhedonia and depression, both frequently reported in PD (3), were then 
assessed with the sucrose preference and forced swim tests (FST) respectively. Sucrose preference as well 
as general consummatory behavior, measured by daily food and water intake, were not affected by the 
6OHDA lesion (Fig. 2C, Fig. S3B). The lesion however decreased the latency to immobility and 
increased immobility time in the FST [p<0.001 in both cases, Welch-corrected t-tests; Fig. 2D], 
representative of a despair-like behavior associated with depression (32).  
Finally, to evaluate deficits in motivation and selective attention (a core feature of PD executive 
dysfunction) (40), the social interaction and novelty discrimination test was used. Loss of dopamine in the 
DLS decreased interaction time in the first part of the test [p=0.007, Welch-corrected t-test; Fig. 2E], an 
ecological indicator of apathy (41). Then, in the discrimination task, the lesioned animals also failed to 
preferentially direct their attention to the novel juvenile, which resulted in a decreased discrimination ratio 
[p<0.001, Welch-corrected t-test; Fig. 2E]. This effect was however not due to a decrease in total social 
interaction during the discrimination task (Fig. S3C), thus excluding a direct interference from the 
decreased motivational state.   
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Taken together, these behavioral results indicate that the loss of DA restricted to the DLS was sufficient to 
reproduce alterations relating to depression, apathy and attentional deficits, which are three of the most 
prevalent symptoms at the time of PD diagnosis (42). 
Gpr88 knock-down in the DMS, but not the DLS, reverses the behavioral deficits. 
Although Gpr88-KD had no effect on horizontal and stereotyped activity in the Actimeter test, 
inactivation in the DMS reversed the deficit in rearing behavior at the 15-minute timepoint [p=0.020, 
Dunnett multiple comparison test; Fig. 3A]. It also increased sensorimotor gating without affecting startle 
amplitude [2W-ANOVA: effect of treatment on % PPI, F(2,78) = 9,79, p<0.001; Fig. 3B].  
Furthermore, whereas Gpr88-KD in either area had no impact on sucrose preference, inactivation in the 
DMS had an antidepressant-like effect in the FST, as it increased latency and reduced immobility time 
[p=0.003 and p=0.021 respectively, Dunnett multiple comparison test; Fig. 3D]. This reduction was 
mediated by an increase in swimming behavior specifically [p=0.028, Dunnett multiple comparison test; 
Fig. S4A]. No effect on consummatory behavior was observed (Fig. S4B). 
Gpr88-KD in the DMS also had a pro-motivational effect as it increased social interaction duration 
[p=0.019, Dunnett multiple comparison test; Fig. 3E]. Finally, whereas the inactivation in both the DLS 
and DMS increased preferential interaction with the novel juvenile in the social discrimination task 
[p=0.004 and p<0.0001, respectively, Sidak multiple comparison test; Fig. 3E], only the effect in the 
DMS was large enough to restore the discrimination ratio [p=0.001, Dunnett multiple comparison test; 
Fig. 3E]. This pro-attentional effect was however not associated with an increase in total interaction time 
during the discrimination task (Fig. S4C). 
To summarize, Gpr88 inactivation in the intact associative DMS, but not the lesioned sensorimotor DLS, 
was thus able to significantly reduce the behavioral deficits that characterized this model of the psychiatric 
symptoms of PD. 
DA loss in the DLS induces molecular alterations in the adjacent DMS. 
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We then assessed the expression of molecular markers of neuronal activity that are known to be 
modulated by 6OHDA lesions. For instance, Prodynorphin (Pdyn) and Proenkephalin (Penk) are 
expressed in direct and indirect pathway MSN (dMSN, iMSN) respectively, where their expression level 
reflects neuronal activity (43). We also evaluated the expression of Glutamate decarboxylase 67 (Gad67), 
an enzyme involved in the synthesis of GABA, as it is considered a proxy for the global level of 
GABAergic transmission in the striatum, arising from MSN and interneurons (44). Strikingly, we found 
that despite the loss of DA being strictly limited to the DLS, significant alterations in the expression of 
these markers were also observed in the adjacent, intact DMS. Indeed, while the lesion expectedly 
decreased Pdyn and increased Penk expression levels in the DLS [p<0.0001 in both cases; multiple t-tests 
followed by Holm-Sidak corrections, here and throughout the next sections; Fig. 4A] (43), the expression 
of both markers was upregulated in the un-lesioned DMS [p=0.020 and p=0.013 respectively; Fig. 4A], 
indicating a local hyperactivity of dMSN and iMSN. Furthermore, Gad67 expression was also 
significantly upregulated throughout the dorsal striatum [p<0.001 in the DLS, p=0.007 in the DMS; Fig. 
4A].  
Then, to investigate the effects of the lesion on intracellular signaling, we chose to focus on the regulator 
of G-protein signaling 4 (RGS4), which is involved in the pathophysiology of PD (45–47) and causally 
linked to GPR88 function (18). While the 6OHDA lesion induced a trend towards a decrease in the 
expression of Rgs4 in the DLS, it significantly increased it in the DMS [p=0.062 and p=0.011, 
respectively; Fig. 4A]. Gpr88 expression remained however unaffected by the loss of DA in either striatal 
area (Fig. S5). 
∆FosB, a transcription factor involved in neuropsychiatric disorders including PD (48), was then chosen 
as a final molecular readout, as its unique accumulation profile confers it a long-lasting effect on the 
regulation of striatal gene networks (49). We found that while ΔFosB expression was locally increased by 
the loss of DA, it was also significantly decreased in the un-lesioned DMS [p<0.001 and p=0.002, 
respectively; Fig. 4B]. 
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Taken together, these results thus indicate that the restricted loss of Substantia Nigra DA inputs to the 
sensorimotor territories of the striatum alters the expression of molecular markers of neuronal activity, 
signaling and transcription beyond the lesioned area, significantly affecting associative territories.   
 
Gpr88 inactivation in the DMS reverses alterations in Rgs4 and ∆FosB expression.   
We then analyzed the effect of Gpr88-KD on the aforementioned molecular markers, and found that 
Gpr88-KD strongly reduced the expression of Gad67 and Rgs4 in the DLS and DMS [in the DLS: 
p<0.0001 for both mRNAs, in the DMS: p<0.001 for Gad67 and p=0.002 for Rgs4; Fig. 5A]. In the DLS, 
Gpr88-KD also significantly decreased the expression of Penk, suggesting a reduction of iMSN 
hyperactivity, and induced a trend towards an increase in Pdyn expression [p<0.0001 and p=0.058, 
respectively, Fig. 5A]. Interestingly, Gpr88-KD had opposing effect on ΔFosB expression in the DLS and 
DMS, reverting in both cases the 6OHDA-induced alterations [p<0.001 and p=0.002, respectively, Fig. 
5B].  
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DISCUSSION  
In our experiments, we showed that reproducing early PD DA loss in the sensorimotor striatum (DLS) of 
rats induced behavioral deficits that are representative of some of the most frequent psychiatric symptoms 
of the disease, without however altering motor behavior. For instance, the DA loss increased immobility 
time in the forced swim test, an indicator of behavioral despair linked to depression (32). It also induced a 
decrease in social interaction and rearing behavior (related to novelty exploration (37)), two parameters 
that have been proposed as ecological and translational measures of apathy (41). These results are also 
coherent with the observations that behavioral and social aspects of apathy are the most affected in PD, 
and that they are specifically associated with depression (50, 51). Furthermore, PD apathy is frequently 
associated with cognitive impairment and dementia (4). In this regard, we also observed that the lesioned 
animals performed poorly in the social novelty discrimination task, suggesting an impairment of selective 
attention (30), a core component of the dysexecutive syndrome experienced by patients (12). 
We however did not replicate deficits relating to anhedonia and sensorimotor gating that had previously 
been reported in other 6OHDA models of the disease using the sucrose preference and prepulse inhibition 
(PPI) tests (39, 52). Anhedonia is frequently reported in PD, but has however been associated with the 
mesolimbic dopamine pathway (53), which we did not affect in our study. Previous studies have also 
found that extensive dopamine loss is required to induce PPI alterations (39). In our experiments, while 
the lesioned rats exhibited a significantly increased startle reaction, they maintained a normal level of 
%PPI, suggesting the presence of efficient compensatory mechanisms. It is thus likely that the lack of PPI 
and sucrose preference alterations in our model is due to the restricted nature of the lesion. 
Importantly, we showed that Gpr88 inactivation in the associative (DMS), but not the sensorimotor (DLS) 
striatum, had pro-motivational, pro-attentional and antidepressant effects, as it reversed the behavioral 
deficits induced by the DA loss, without however affecting motor behavior. Gpr88-KD in the DMS also 
increased sensorimotor gating in the PPI test, indicating an increased efficiency of pre-attentive 
information processing, which could underlie the pro-attentional effect in the social novelty discrimination 
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task. Interestingly, computational models of PD psychosis have linked the emergence of hallucinations to 
deficits in such gating and attentional processes (6), suggesting that Gpr88-KD may constitute a relevant 
target to evaluate in animal models of this symptom.  
Our molecular investigations then allowed us to identify markers that were involved in both the effect of 
DA loss and of Gpr88-KD. First of all, while a previous study had reported that 6OHDA lesions induced a 
decrease in Gpr88 mRNA and protein expression after 1 and 4 weeks (16), we did not observe such an 
effect at 6 weeks, suggesting a time-dependent recovery of Gpr88 expression following DA loss.  
At the level of neuronal activity markers, we observed that the lesion locally induced a decrease in Pdyn 
and an increase in Penk and Gad67 expression levels, reflecting the imbalance in neuronal activity that has 
previously been characterized in PD models (43, 44). However, this restricted loss of DA also led to 
molecular changes in the neighboring associative territory of the striatum (DMS). Indeed, in the DMS, all 
of the aforementioned markers were significantly elevated, suggesting a compensatory overactivity of 
neurons in response to DA depletion of the DLS.  
We found that the effects of Gpr88-KD in the lesioned DLS were mediated by a significant decrease in 
the expression of Penk and Gad67. This result indicates that Gpr88-KD preferentially affects iMSN, 
which is coherent with the receptor’s relative enrichment in this neuronal type (16), and the 
hypersensitivity to D2 agonists that has been consistently reported in Gpr88-KO mice (18, 20). As GPR88 
is also known to modulate enkephalin receptor DOR signaling (19), the reduction in Penk expression we 
observed following Gpr88-KD may thus partly result from a potentiation of this receptor’s effects. In the 
DMS, Gpr88-KD reduced Gad67 overexpression without however significantly affecting Penk or Pdyn, 
suggesting a potential decrease in GABA interneuron activity (44), in which GPR88 expression has been 
reported (16).  
We then investigated Rgs4 as a marker of intracellular signaling. RGS4 is a GTPase accelerating protein 
which negatively regulates the signaling of Gi/o- and Gq- associated receptors that have been involved in 
PD pathophysiology such as D2/D3 (54), mGluR 5(55) and M4 (46). Previous studies have reported slight 
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decreases in striatal Rgs4 expression in patients (45) and in rodents following 6OHDA injections (56). In 
our model, while we did observe a trend towards a decreased expression of Rgs4 in the lesioned DLS 
(p=0.06), it was also strikingly elevated in the DMS. This overexpression was however completely 
reversed by Gpr88-KD, an effect that is in line with findings from KO mice (18, 19). Interestingly, in 
models of PD, inhibition or loss of Rgs4 has been shown to have potent anti-parkinsonian effects (57), 
notably by restoring LTD in iMSN (47). Although these reported effects have been encouraging, 
translation to the clinic has been impeded by the high risk of side-effects due to RGS4’s ubiquitous 
presence (58). Targeting GPR88 may thus constitute a unique strategy to bypass these limitations by 
inhibiting RGS4 with high spatial relevance, as GPR88 is exclusively expressed in the CNS, and is 
extremely enriched in the striatum, where its expression levels match the typical pattern of dopamine loss 
(59). 
Finally, we observed contrasting effects of the lesion and Gpr88 inactivation on the expression of 
transcription factor ∆FosB. For instance, while ∆FosB accumulation in PD has previously been linked to 
the effects of L-DOPA treatment (48, 60), we also observed an increase in the DLS of the lesioned rats. 
This unexpected effect could be due to stimulation of hypersensitive D1 receptors in the DLS, resulting 
from a “volume transmission” effect from the un-lesioned striatum (61). In the DMS however, there was a 
significant decrease in ∆FosB expression, which was reversed by Gpr88-KD. Previous studies have shown 
that in the dorsal striatum, D2 stimulation increases ∆FosB accumulation, which in turn sensitizes the D1 
receptor (62–64). One could thus speculate that the increased expression of ∆FosB we observed in the 
DMS following Gpr88-KD may result from a potentiation of D2 signaling through Rgs4 inhibition. 
Furthermore, ∆FosB-mediated D1 sensitization may thus potentiate dMSN signaling, and help promote 
goal-directed behavior. For example, the antidepressant effect of Gpr88-KD observed in the FST may be 
due to its modulation of ∆FosB, as fluoxetine is also known to increase the expression of this transcription 
factor in the DMS (65). Nevertheless, the fact that Gpr88-KD had an opposing effect on ∆FosB 
.CC-BY-NC-ND 4.0 International licenseIt is made available under a 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/617456doi: bioRxiv preprint first posted online Apr. 24, 2019; 
20 
 
expression in the DLS suggests a complex interaction with dopamine signaling, which deserves to be 
further investigated.  
To conclude, our results support the relevance of GPR88 as a therapeutic target for the psychiatric 
symptoms of PD, as we demonstrate in our model that knocking-down its expression in the associative 
striatum reduces the behavioral deficits and normalizes the expression of Rgs4 and of ∆FosB, which have 
both been previously linked to PD pathophysiology. 
Beyond supporting GPR88 as a potential therapeutic target, this study may also provide insights regarding 
the etiology of the psychiatric symptoms of PD. Indeed, while these symptoms have been linked to 
alterations in multiple neurotransmitter systems (26), clustering studies of de novo patients suggest that the 
loss of striatal dopamine in particular may play an important role in their emergence (66, 67). This idea is 
further supported by studies in rodent models, which have consistently shown that inducing extensive DA 
loss throughout the striatum could induce representative behavioral deficits (52). Nevertheless, these 
models haven’t necessarily accounted for the frequent pre-motor appearance of these symptoms, when the 
DA loss is mainly limited to sensorimotor areas of the striatum (25). In this regard, our results show that 
such a restricted loss of dopamine is per se sufficient to reproduce these behavioral alterations in an 
animal model.  
These psychiatric aspects of PD have however typically been associated with DA dysfunctions in 
associative networks (DMS) (26), which are relatively preserved in early stages of the disease as well as in 
our model. Nevertheless, we did observe an overexpression of neuronal activity markers in the DMS, 
suggesting possible interactions between striatal areas. Interestingly, fMRI studies of PD patients have 
also found that while functional connectivity decreased in the dopamine-deprived sensorimotor networks 
of the basal ganglia, increases could also be observed in associative networks (68–70). These increases are 
thought to reflect early PD allostatic mechanisms, by which associative networks may expand or 
strengthen their connectivity to compensate for the loss of DA in sensorimotor territories. Although the 
underlying mechanisms are currently unknown, recently characterized striato-nigro-striatal cellular 
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pathways may provide a system for such lateral transfer of information (71). However, due to the resulting 
overlap of networks within limited striatal computational resources, it has been suggested that this 
compensatory mechanism could lead to a “neural bottleneck” or “overload” of associative networks, and 
impairment in related behaviors (36, 68, 69). This hypothesis could thus explain the emergence of 
psychiatric deficits relating to cognition and motivation during the earliest stages of PD and in our model 
of the disease, before the loss of DA affects associative networks.  
In this context, the results from our investigations may suggest a molecular mechanism for the “overload” 
hypothesis. Indeed, as Dynorphin downregulates both nigrostriatal dopamine release and the induction of 
immediate early genes in MSN (such as Fos family genes) (43), Pdyn overexpression in the DMS of 
6OHDA-lesioned rats may act as a throttle on dMSN activity and on the execution of goal-directed 
behaviors. Furthermore, the increased expression of Rgs4 we observed in the DMS might also contribute 
to this effect by reducing the inhibitory control of Gi/o and Gq receptors over iMSN activity, which could 
further distort action selection and execution.  
Although imbalances in DMS/DLS dynamics are emerging as key players in the pathophysiology of basal 
ganglia disorders such as addiction (72) and OCD (73), this study is the first to our knowledge to enquire 
this aspect in a rodent model of PD. Several elements nevertheless need to be further investigated. For 
instance, behavioral tests assessing specific cognitive and motivational parameters would be welcome, to 
further characterize the effects of the lesion and of Gpr88-KD. As the model we used recapitulates aspects 
of early-stage PD, it will also be necessary to assess the effects of Gpr88-KD in models of advanced PD, 
presenting more extensive DA loss and alterations in other neurotransmitter systems. Furthermore, while 
our molecular experiments have provided some clues regarding the mechanisms involved, additional in-
depth studies are required, as very little is known about the signaling pathways regulated by GPR88 in 
different striatal cell types (dMSN/iMSN/interneurons).   
Provided that these questions can be answered, there is still an essential issue to consider in order to 
advance the translational process to the clinic. Specifically, while GPR88’s restricted expression makes it 
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an ideal therapeutic target, no antagonist has so far been developed for this orphan receptor. It is thus 
crucial to develop lead identification efforts. Nevertheless, gene therapy approaches have showed 
successful applications for PD (74). A recent study notably found that a GAD gene therapy approach 
targeting the subthalamic nucleus reduced motor impairment in patients by inducing changes in basal 
ganglia connectivity (75) that are reminiscent of those we observed in our model. Based on our findings, 
GPR88 gene therapy could thus constitute a highly relevant non-dopaminergic strategy to treat the 
psychiatric symptoms of PD through striatal-level modulation of allostatic basal ganglia function.  
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FIGURE LEGENDS 
 
Figure 1 – Stereotaxic injections induce a restricted loss of nigrostriatal dopaminergic projections and an 
efficient knock-down of Gpr88 expression in discrete striatal areas.  
(A) Representative images of 6-hydroxydopamine (6OHDA)-lesioned striata. Coronal sections stained for 
Tyrosine hydroxylase (TH) by immunofluorescence (+1,2 to +0,2 mm anterior to bregma), superimposed 
on the Paxinos and Watson rat brain atlas (29) for anatomical reference. (B) Quantification of the extent of 
Th signal loss in the dorsolateral (DLS), dorsomedial (DMS), and ventral striatum (VS). Compared to 
SHAM-injected rats, the 6OHDA induced a mean loss of 48% of the TH signal in the DLS, without 
affecting the DMS and VS. (C) Schematic representation of the lentiviral construct used to transduce the 
targeted striatal regions, two weeks after the 6OHDA/SHAM injection. (D) Representative images of DLS 
or DMS transduced striata. The lentiviruses were injected at two coordinates anterior to bregma: +1,2 and 
+0,2mm. For visibility purposes, a LUT was applied to the images in ImageJ in order to visualize the GFP 
fluorescence on a blue background. The photographs were then superimposed on the Paxinos and Watson 
rat brain atlas (29) for anatomical reference. (E) In situ hybridization shows a strong suppression of Gpr88 
expression induced by miR-Gpr88, but not miR-neg. (F) Quantification of the in situ hybridization signal 
for Gpr88 mRNA following miR-neg or miR-Gpr88 injections in the DLS or DMS. The values were 
normalized to those of the control group (SHAM + miR-neg). They are presented as mean ± SEM and 
were compared with Holm-Sidak corrected multiple t-tests. **** p<0.0001. 
 
Figure 2 – Dopamine loss in the dorsolateral striatum (DLS) reproduces psychiatric symptoms of PD.  
(A) Horizontal, stereotyped and rearing behaviors were measured with the Actimeter test 4 weeks after the 
6-hydroxydopamine (6OHDA) lesion. The loss of dopamine (DA) only affected rearing at the 15-minute 
timepoint. (B) The lesion also increased the startle amplitude in response to a loud stimulus (110dB), 
without however affecting % Prepulse Inhibition at any of the tested prepulse intensities. (C) Sucrose 
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preference was not affected by the 6OHDA lesion. (D) The lesion nevertheless induced a depressive-like 
behavior, reflected by a decrease in latency and an increase in the immobility count. (E) The 6OHDA 
lesion also reduced social interaction duration, abolished preferential interaction with a novel juvenile, and 
impaired the novelty discrimination ratio. Data are presented as mean ± SEM. When two groups were 
compared, two-tailed, Welch-corrected t-tests were performed. In the case of interactions with additional 
factors, two-way ANOVAs, followed by Sidak’s multiple comparison test were used (Actimeter data, 
%PPI, and P2 investigation time). *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
 
Figure 3 – Gpr88 knock-down in the dorsomedial (DMS), but not the dorsolateral striatum (DLS), 
reverses the behavioral deficits. (A) Gpr88-KD in the DMS reversed the rearing deficit at the 15-minute 
timepoint, without affecting horizontal or stereotyped behavior. (B) While Gpr88-KD did not affect startle 
amplitude, it increased the % prepulse inhibition at the lower prepulse volumes. (C) Sucrose preference 
was not affected by Gpr88-KD. (D) Gpr88-KD in the DMS had an antidepressant-like effect as it 
increased latency and decreased the immobility count in the FST. (E) Gpr88-KD in the DMS increased 
social interaction duration, and restored novelty preference and discrimination ratio. Gpr88-KD in the 
DLS selectively increased novelty preference, but the effect was not strong enough to restore the 
discrimination ratio. Data are presented as mean ± SEM. For reference, a dashed horizontal line indicates 
the values from the control group (SHAM + miR-neg), that were presented in Fig. 2. When the three 6-
hydroxydopamine (6OHDA) groups were compared, one-way ANOVAs followed by Dunnett’s multiple 
comparisons test were performed. In the case of interactions with additional factors, two-way ANOVAs, 
followed by the Dunnett multiple comparisons test were used (Actimeter data, %PPI, and P2 investigation 
time). *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
 
 
Figure 4 – Molecular changes induced by dopamine loss in the DLS also affect the adjacent DMS.  
(A) The lesioned rats had an increased expression of Gad67 and Penk in both the dorsolateral (DLS) and 
dorsomedial striatum (DMS). However, whereas Pdyn expression was strongly decreased in the lesioned 
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DLS, it was increased in the intact DMS. The loss of dopamine (DA) also resulted in an increased Rgs4 
expression in the DMS. (B) The 6-hydroxydopamine (6OHDA) lesion induced a local increase in ∆FosB 
expression, but a decrease in the un-lesioned DMS. The values were normalized to those of the control 
group (SHAM + miR-neg). Data are presented as mean ± SEM, and were compared using multiple t-tests 
with Holm-Sidak corrections. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
 
Figure 5 – Gpr88 knock-down modulates markers of neuronal activity, signaling and transcription. (A) 
Gpr88-KD decreased Gad67, Penk and Rgs4 expression levels. It however did not significantly affect 
Pdyn expression. (B) Gpr88-KD reversed ∆FosB expression in a dopamine-dependent manner 
(dorsolateral/dorsomedial striatum). The values were normalized to those of the control group (SHAM + 
miR-neg). They are presented as mean ± SEM, and were compared using multiple t-tests followed by 
Holm-Sidak corrections. **p<0.01, ***p<0.001, ****p<0.0001. 
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